Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in the Serum and Cerebrospinal Fluid of Patients With Coronavirus Disease 2019 and Neurological Symptoms

J Infect Dis. 2022 Mar 15;225(6):965-970. doi: 10.1093/infdis/jiab153.

Abstract

Antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in serum and cerebrospinal fluid (CSF) samples from 16 patients with coronavirus disease 2019 and neurological symptoms were assessed using 2 independent methods. Immunoglobulin G (IgG) specific for the virus spike protein was found in 81% of patients in serum and in 56% in CSF. SARS-CoV-2 IgG in CSF was observed in 2 patients with negative serological findings. Levels of IgG in both serum and CSF were associated with disease severity (P < .05). All patients with elevated markers of central nervous system damage in CSF also had CSF antibodies (P = .002), and CSF antibodies had the highest predictive value for neuronal damage markers of all tested clinical variables.

Keywords: COVID-19; CSF; IgG; SARS-CoV-2; neurological symptoms; serology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antibodies, Neutralizing / blood
  • Antibodies, Viral / blood*
  • Antibody Formation
  • Biomarkers / blood
  • Biomarkers / cerebrospinal fluid
  • COVID-19 / blood
  • COVID-19 / cerebrospinal fluid
  • COVID-19 / complications
  • COVID-19 / diagnosis*
  • Female
  • Humans
  • Immunoglobulin G / blood*
  • Male
  • Middle Aged
  • Nervous System Diseases / blood*
  • Nervous System Diseases / cerebrospinal fluid*
  • Nervous System Diseases / diagnosis
  • Nervous System Diseases / etiology
  • SARS-CoV-2 / genetics
  • SARS-CoV-2 / immunology
  • SARS-CoV-2 / isolation & purification*
  • Spike Glycoprotein, Coronavirus

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Biomarkers
  • Immunoglobulin G
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2